Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Community Leaders, HIV Doctors Oppose Hepatitis C Treatment Barriers

A coalition of hepatitis C advocacy organizations and medical providers has issued an open letter to the Secretary of Health and Human Services calling for an end to restrictions on access to hepatitis C treatment by private insurers and public payers seeking to avoid the cost of newly approved direct-acting antivirals. HIV medical providers also called for reducing barriers to treatment, including restrictions on which medical specialists may treat people with hepatitis C.

Published
17 September 2014
From
HIVandhepatitis.com
Gilead’s Proposed Hepatitis C Medicines License: How Badly Will it Miss the Target?

Gilead’s proposed license, and its limitations, is important because Gilead has applied for patents on Sovaldi® and ledipasvir in many countries, although a number of countries in the probable licensed territory are without patents. As a patent holder, Gilead generally has rights to exclude competitors and charge monopoly prices on these life-saving medicines. The anticipated license will set precise terms on which companies can make generic equivalents and where and under what circumstances those generics can be sold. In other words, Gilead sits in the driver’s seat and has enormous power to decide who does and doesn’t get more affordable access to generics of assured quality.

Published
17 September 2014
From
Infojustice
Access to sofosbuvir in middle-income countries

Gilead is excluding 51 middle income countries (MICs) from its license for sofosbuvir, an oral hepatitis C drug. Across these MICs, where nearly 50 million people are infected with hepatitis C virus (HCV), lack of access to generic sofosbuvir will increase the total cost of curing hepatitis C by an estimated $60 billion dollars, according to I-MAK’s analysis.

Published
17 September 2014
From
I-MAK
Gilead Deal to Sell Sovaldi in Poor Countries Meets Criticism

more than three dozen patient advocacy groups say the licensing deals do not go far enough, because the deals excludes many middle-income countries – such as Brazil, China, Turkey, Thailand and Ukraine – where governments and individuals may not be able to afford the Gilead drug. The patient groups are concerned the licenses will preclude the generic drug makers from selling lower-cost versions to those countries and potentially excluding millions of patients with hepatitis C from gaining access to treatment.

Published
16 September 2014
From
Pharmalot
Clash between state, drugmaker heats up as Legislature takes up Hepatitis C cost

Citing the 12-week treatment cost of $84,000, Oregon officials want to put strict new restrictions on access to the drug, especially for those in earlier stages of the disease. Commercial insurers already have some access rules, but are watching the state's battle closely.

Published
16 September 2014
From
The Oregonian
Gilead signs pact with 7 firms for cheap copies of hepatitis C drug

Gilead's licensing agreement with firms including India's Cipla Ltd and Ranbaxy Laboratories Ltd clears the way for the launch of a cheap generic version of the drug in 91 developing countries that make up 54 percent of the total global hepatitis burden.

Published
15 September 2014
From
Reuters
Simeprevir in hepatitis C: added benefit for certain patients

Added benefit for untreated and relapsed patients with unclear extent; major added benefit for non-responders; missing data for patients with HIV coinfection and genotype 4 patients.

Published
10 September 2014
From
German Institute for Quality and Efficiency in Health Care
Gilead close to sending $84,000 drug to poor countries

Gilead Sciences Inc. is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan.

Published
09 September 2014
From
Bloomberg
MSF urges BMS to make daclatasvir accessible in low-and middle-income countries

Welcoming the EMA's approval of daclatasvir on August 27, 2014, the MSF said that the BMS must rapidly register daclatasvir in those countries with a high burden of hepatitis C, especially in those countries with a high prevalence of genotype 3. It also urged BMS to ensure daclatasvir is affordable in those countries with a high burden of hepatitis C.

Published
01 September 2014
From
Pharmabiz
European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection

Bristol-Myers Squibb Company today announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus (HCV) infection in adults. Daklinza, when used in combination with sofosbuvir (Sovaldi), is an all-oral, interferon-free regimen that provided cure rates of up to 100% in clinical trials

Published
27 August 2014
From
Bristol-Myers Squibb
← First12345...43Next →

Filter by country